anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Ingested dental prosthesis are susceptible to impaction in the gastrointestinal tract due to their sharp edges, size and contour. Delays in presentation arise from the lack of clear history of ingestion and misdiagnosis occurs due to the radiolucency of denture material on plain radiography. An acquired, non-malignant tracheo-oesophageal fistula (TOF) may develop from a chronically impacted denture. Surgical management of a TOF secondary to denture is a challenging clinical problem that is rarely reported in the literature and no previous case reports have described the two-staged reconstruction approach that we present here.
CASE PRESENTATION: We report a case of a male in his early 60s who presented to an acute general hospital with symptoms ongoing for over one year of dysphagia, recurrent chest infections and weight loss. Barium swallow and computed tomography identified an ingested dental prosthesis (denture) that had caused a TOF. He was transferred to our specialist thoracic surgery unit where an attempt to remove the foreign body endoscopically was abandoned due to firm impaction and risk of further injury. The subsequent multi-disciplinary management of this complex case required a two-staged reconstruction approach. The first procedure involved extracting the foreign body, repairing the underlying defects with tracheal resection and anastomosis, and creating an oesophageal diversion with cervical oesophagostomy. The second procedure achieved continuity of the gastrointestinal tract with gastric pull-up and pharyngo-gastric anastomosis. Following rehabilitation, the patient was discharged on oral intake alongside percutaneous jejunostomy feeding.
CONCLUSIONS: Early recognition and removal of impacted dental prosthesis is essential to prevent morbidity and mortality. Delayed diagnosis can lead to acquired TOF with associated consequences such as recurrent pulmonary infection, mediastinitis and nutritional deficit. Challenges we encountered, such as failed attempts at endoscopic retrieval and the difficult dissection of fibrotic tissue, were directly due to the delayed identification of the denture. We highlight the importance of holding a high index of clinical suspicion of foreign body ingestion in dental prosthesis wearers who present with recurrent chest infections and ongoing dysphagia. We also promote the need for a collaborative multi-disciplinary approach in the surgical management of complex cases.
Chronic rhinosinusitis (CRS) is a persistent inflammatory disease of the nasal cavity and paranasal sinuses. Traditional classification is denoted by the presence (CRSwNP) or absence of nasal polyps (CRSsNP). Particularly, CRSwNP is distinguished by the presence of infiltrating cells and inflammatory markers in the nasal mucosa. Patients with CRSwNP in Western countries predominantly display a type 2 endotype, whereas those in Asian regions display a mixed type 2 endotype. Nevertheless, recent transcriptome analyses have revealed two types of nasal polyps - type 2 and non-type 2 polyps, suggesting that geographical differences in endotypes likely resulted from the different proportions of each endotype. Moreover, various endotypes of CRSsNP have been identified, making phenotype a crucial factor for predicting treatment efficacy. Type 2 endotypes, designated as eosinophilic CRS (ECRS) in Japan, are characterized by severe eosinophilic infiltration into the paranasal sinus tissue and are particularly refractory. In this review, we discuss the latest developments in ECRS. We also provide recent findings on the involvement of nasal epithelial cells in pathogenesis.
After an inclusion visit to ensure the adolescents' ability to complete the entire study, they will then complete 6 experimental visits: i) before their weight loss program (T0); ii) then a visit after a weight loss of 5% (T-5%); iii) after losing 10% of their weight (T-10%); iv) after 12 weeks of treatment (T1); v) after 24 weeks of treatment (T2) and; vi) after 4 months of post-intervention follow-up (T3).

During each of these visits, densitometric (body composition and bone structure) and anthropometric (height, body mass, waist circumference, hip circumference) measurements will be taken. Their resting metabolism as well as their energy consumption during a low-intensity incremental walking exercise will be measured by indirect calorimetry. Their sleep metabolism will be assessed over one night using Dreem headbands and their dietary control assessed during a calibrated test meal (satiety quotients and food reward). Their perception of health and quality of life, as well as the perception of their physical condition and their dietary profiles will be evaluated by questionnaire. The cardiovascular profile will also be assessed by measuring sinus variability, hepatic steatosis, arterial stiffness and the resistance and reactance of the respiratory system. Finally, a fasting blood sample will be taken.
Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
After 4 doses of nivolumab, if the patient has PR, stable disease (SD), or progressive disease (PD), the patient will switch to nivolumab-GDP/L-aspa treatment. After 6 cycles of treatment, if CR is achieved, the patient will continue on single agent nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment.
Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
Systems and methods are described herein for predictive heart valve simulation. The systems and methods described herein can include segmenting anatomical region of a heart of a patient from image data characterizing the heart of the patient. Anatomical model data that can include three-dimensional shapes of the anatomical regions of the heart can be generated based on the image data. The anatomical model data can be used to generate anatomical model data. The analytical model data can include a three-dimensional mesh of the anatomical regions of the heart. A deformed analytical model that can be indicative of a deformed position of the anatomical regions of the heart and a deformed position of the surgical object can be generated based on the analytical model data.
There is a large body of research performed to investigate the etiology of contralateral radiculopathy. However, limited information exists to determine its incidence, underlying pathomechanics, and strategies for management. Therefore, this case series aimed to describe a new clinical condition for the first time in the medical literature called Ankle Spine Syndrome or "RAFFET Syndrome II". This syndrome was reported in 6 patients (2 males and 4 females) out of 1000 patients with a history of chronic ankle injuries affecting their calf muscles' strength throughout the last 3 years. The patients suffered from unresolved CLBP with radiculopathy contralateral to their calf muscle atrophy (i.e., an ipsilateral calf muscle weakness induces contralateral lumbar radiculopathy) that did not respond to physical therapy or any medication for long. Open and closed chain strengthening exercises for the calf muscle were performed. The strengthening exercises include; double leg calf raise (i.e., straight and bent knees), single leg calf raise (i.e., straight and bent knee), seated calf raise, and wall sit calf raise. The patients' long-term back pain and function resolved greatly. By including lumbar stabilization exercises, core training, and myofascial release therapy, the symptoms resolved completely. Furthermore, with a follow-up after 6 months of a tailored home exercise program, the clinical outcome measures still resolved completely.
The invention provides vaginal compositions suitable for preventing conception and transmission of sexually transmitted diseases comprising a spermicidal agent and a peroxygen compound. Preferably, the spermicidal agent is nonoxynol-9. Also preferably, the peroxygen compound is hydrogen peroxide. The spermicidal agent is preferred at about 3% by weight. The peroxygen compound is also preferred at about 3% by weight. In other aspects, the invention provides these compositions at a pH of about 4, preferably about 3 or lower. This pH is favorably maintained with lactic acid. These compositions are preferably encapsulated in the form of a gel.
Patients randomized to this cohort will receive enzalutamide and a titrated dose of CORT125281. Enzalutamide will be continued at the dose currently tolerated by the patient at screening.
PURPOSE: To obtain a detergent composition which is superior to conventional detergents in the texture of foam, such as slipperiness and creaminess of foam, and foam breakability and greatly reduced in irritativeness to the skin by blending a sugar and/or a sugar alcohol and a maltitol hydroxy aliphatic ether(MHE). CONSTITUTION: Component (A) comprising a sugar (e.g. glucose) and/or a sugar alcohol (e.g. sorbitol) and an MHE (B) of the formula (wherein A is a residue obtained by removing n hydroxyl groups from maltitol; R<1> and R<2> are each H, or 1-20C alkyl or branched alkyl; and n is 1 or 2) are blended respectively in amounts of 5-45wt.% and 0.1-10wt.% based on the total weight of a detergent composition. The ratio of the component A to the total surfactants in the detergent composition is preferably (3:1) to (1:3). It is desirable to use an anionic surfactant together with an amphoteric surfactant although they may be used alone. The surfactants are added in an amount of 5-30wt.% when liquid and 50-95wt.% when solid.
Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels \> 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
The invention relates to a nucleic acid aptamer, in particular to a nucleic acid aptamer H11 with targeting inhibition effect on vibrio anguillarum, and the nucleic acid sequence is shown in SEQ. NO. 1. And the application of the aptamer H11 in preparing Vibrio anguillarum inhibitors. The invention takes vibrio anguillarum as a target, and selects an aptamer (H11) screened by a Cell-SELEX technology to analyze the antibacterial function of the aptamer. Has the advantages of short screening period, simple and convenient chemical synthesis, capability of replacing antibiotics and the like, and has better application prospect. Provides a theoretical basis for further research on inhibitory aptamers.
Patients will be included in this trial if they have relapsed or refractory ALK+ ALCL after at least one line of conventional chemotherapy or if they are ineligible for conventional chemotherapy.

Imatinib will be given continuously starting from day 1 of the first cycle at an oral dose of 100mg daily. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle. BV will be given 3 weekly starting on day 1 at a dose of 1.8 mg/kg body weight. In the absence of a dose limiting toxicity (DLT) i.e. haematological toxicity ≥ grade 2, non- haematological toxicity ≥ grade 3, after 3 weeks of therapy, and in the presence of a clinical response (CR or PR) after cycle 1, the BV dose will continue every 3 weeks for 48 weeks. Dose modifications and stopping rules will be introduced as described in chapter 6. In case of progression at any time during the study the patient will go off trial and receive salvage treatment.
PURPOSE:The titled composition, consisting of a dilong-chain dishort-chain type quaternary ammonium salt having an iodine value within a specific range, i.e. unsaturated bonds within a specific range of number and a specific anionic surfactant in combination and having improved gloss and hair conditioning. CONSTITUTION:A shampoo composition containing 0.1-5wt% quaternary ammonium salt, having 35-100 iodine number and expressed by formula I (R1 and R2 are alkyl, etc.; R3 and R4 are methyl, etc.; X<-> is anion) and 5-25wt% one or two or more selected from anionic surfactants expressed by formula II, III and IV (R is alkyl or alkylphenyl: R' is alkylene,; n is 0-6; OS is acid group of anionic surfactant obtained by sulfonating an olefin; M is alkali metal ion, etc.; n is the valence of M).
This article aims to analyse the relationship between physical activity (PA) environment at schools, sex, age, and obesity in children, using a network approach. This is a cross-sectional study, with 1,200 children (8.1±1.0 years old) from eight public schools in the same municipality. Weight and height measurements were assessed to calculate the Body Mass Index (BMI) and classified as healthier weight or overweight. To assess the PA environment at school, a interview with the school´s manager was conducted. The association between the PA environment at school and obesity was tested using a Network Analysis performed on the Jasp software. Positive associations between BMI and Physical Education classes (0.847), physical education teacher (0.349), break duration (0.564), and indoor sports court (0.662) were observed. Negative associations were seen with sex (-0.212) age (-0.387), extracurricular PA (-0.492), and playground (-0.557). Additionally, the centrality indicators highlighted extracurricular PA (1.789) as the variables with the highest betweenness values, and BMI with the highest closeness (2.239) and strength (1.230) values. Extracurricular PA and the presence of playgrounds in school´s environment are associated with healthier weight in low-income children.
This is an experimental, randomized controlled, single-blind study. The study was conducted with the parents of children with CP aged 8-16 years, who went to the rehabilitation centers in a randomized controlled manner between 11 October 2021 and 11 November 2022 to receive education and treatment. The sample consisted of 73 parents, the study group (n=35), and the control group (n=38). Parents in the study groups were given education-support in accordance with their needs in the educational topics specified in the Parent Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, the Needs Determination Form, the Comfort Behaviors Checklist (KDKL), the Parent Form of the Quality of Life Scale for Children (PIDQ) and the Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before, 1 month and 3 months after the education. The control group's data were collected at the same time as the other groups. Descriptive statistics, Pearson chi-square, Fisher exact chi-square, Student-t, and ANOVA were used in the analysis of the data.
Whether empirical therapy with carbapenems positively affects the outcomes of critically ill patients with bacterial infections remains unclear. This study aimed to investigate whether the use of carbapenems as the initial antimicrobial administration reduces mortality and whether the duration of carbapenem use affects the detection of multidrug-resistant (MDR) pathogens. This was a post hoc analysis of data acquired from Japanese participating sites from a multicenter, prospective observational study [Determinants of Antimicrobial Use and De-escalation in Critical Care (DIANA study)]. A total of 268 adult patients with clinically suspected or confirmed bacterial infections from 31 Japanese intensive care units (ICUs) were analyzed. The patients were divided into two groups: patients who were administered carbapenems as initial antimicrobials (initial carbapenem group, n = 99) and those who were not administered carbapenems (initial non-carbapenem group, n = 169). The primary outcomes were mortality at day 28 and detection of MDR pathogens. Multivariate logistic regression analysis revealed that mortality at day 28 did not differ between the two groups [18 (18%) vs 27 (16%), respectively; odds ratio: 1.25 (95% confidence interval (CI): 0.59-2.65), P = 0.564]. The subdistribution hazard ratio for detecting MDR pathogens on day 28 per additional day of carbapenem use is 1.08 (95% CI: 1.05-1.13, P < 0.001 using the Fine-Gray model with death regarded as a competing event). In conclusion, in-hospital mortality was similar between the groups, and a longer duration of carbapenem use as the initial antimicrobial therapy resulted in a higher risk of detection of new MDR pathogens.IMPORTANCEWe found no statistical difference in mortality with the empirical use of carbapenems as initial antimicrobial therapy among critically ill patients with bacterial infections. Our study revealed a lower proportion of inappropriate initial antimicrobial administrations than those reported in previous studies. This result suggests the importance of appropriate risk assessment for the involvement of multidrug-resistant (MDR) pathogens and the selection of suitable antibiotics based on risk. To the best of our knowledge, this study is the first to demonstrate that a longer duration of carbapenem use as initial therapy is associated with a higher risk of subsequent detection of MDR pathogens. This finding underscores the importance of efforts to minimize the duration of carbapenem use as initial antimicrobial therapy when it is necessary.
Participants in this arm will use the air up® drinking system with an orangeade-flavored pod. Similar to Arm 1, the intervention will assess the impact of the flavored scent on water consumption and health outcomes, using the same methods of evaluation.
Among the physiotherapy and rehabilitation approaches applied for the problems affecting the quality of life in Multiple Sclerosis; Exercises for muscle strength loss, balance coordination exercises, electrical stimulation, orthotic approaches, breathing and swallowing exercises, and Proprioceptive Neuromuscular Facilitation (PNF) techniques are included. Among the respiratory dysfunctions are seen in MS patients: abnormal respiratory control, respiratory muscle weakness, bulbar dysfunction/respiratory failure, and sleep breathing disorders can be cited as examples. Significant expiratory weakness develops in MS patients with the progression of the disease, and the accompanying upper extremity involvement exacerbates this problem. It should not be ignored that swallowing-respiratory coordination and ultimately swallowing can be affected by the deterioration of respiration in MS patients. Among the neurophysiological approaches, the PNF technique; is known to have positive effects on tidal volume, respiratory rate, and minute ventilation parameters in neurological patients. Respiratory patterns of PNF can be applied alone or in combination with other extremity patterns. This study aims to examine the effect of using PNF breathing techniques in combination with upper extremity and trunk on MS patients on respiratory and swallowing functions.
Hyperuricemia (HUA) is a symptom of high blood uric acid (UA) levels, which causes disorders such as gout and renal urinary calculus. Prolonged HUA is often associated with hypertension, atherosclerosis, diabetes mellitus, and chronic kidney disease. Studies have shown that gut microbiota (GM) affect these chronic diseases. This study aimed to determine the relationship between HUA and GM. The microbiome of 224 men and 254 women aged 40 years was analyzed through next-generation sequencing and machine learning. We obtained GM data through 16S rRNA-based sequencing of the fecal samples, finding that alpha-diversity by Shannon index was significantly low in the HUA group. Linear discriminant effect size analysis detected a high abundance of the genera Collinsella and Faecalibacterium in the HUA and non-HUA groups. Based on light gradient boosting machine learning, we propose that HUA can be predicted with high AUC using four clinical characteristics and the relative abundance of nine bacterial genera, including Collinsella and Dorea. In addition, analysis of causal relationships using a direct linear non-Gaussian acyclic model indicated a positive effect of the relative abundance of the genus Collinsella on blood UA levels. Our results suggest abundant Collinsella in the gut can increase blood UA levels.
FIELD: medicine, phytotherapy, endocrinology. SUBSTANCE: invention relates to the development of medicinal agents of natural origin for treatment of patients with thyroid diseases. Invention proposes agent comprising mushroom an aqueous extract grown on surface of wetted medium, maize seeds, planted oat, fish khya-ma, to-kal, ovate distaff thistle roots, khya-gu roots, gentian roots and sea kale. Invention proposes also method for preparing agent that involves milling mushroom mycelium followed by addition of milled sea kale and mixture is subjected for extraction with distilled water. Prepared mixture is brought about to boiling, kept at the room temperature and ready extract is separated from precipitate at temperature 6 C. Agent prepared by this method regulates hypo- and hyperfunction of thyroid and can be used as prophylactic agent for prevention of thyroid diseases and tonsillitis. EFFECT: improved preparing method, valuable medicinal properties of agent. 8 cl, 1 tbl, 2 ex
PURPOSE:An useful antisolid tumor agent, containing a specific cembrane type diterpene compound as an active ingredient, capable of preventing solid cancer as an anticarcinogenic promoter and exhibiting action of inhibiting the evolution and multiplication of developed solid cancer. CONSTITUTION:An antisolid tumor agent containing a cembrane diterpene compound expressed by formula I or II (R is H or acyl) as an active ingredient. In use, the above-mentioned compound alone or in combination with a carrier acceptable as a drug is administered. The treating dose is normally 50mug-1,000 mg/kg.day for parenteral administration and 100mug-2,000mg/kg.day for oral administration. The amount of the active ingredient is preferably within the range of 25-100wt% for a capsule, etc., and within the range of 1-10wt% for an injection. The compound expressed by formula I or II is separated from a lipid fraction of an extract obtained from Sarcophytum glaucum by silica gel column chromatography.
During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.